Abstract Anticoagulation and antiplatelet drugs are among the most commonly used medical drugs. In addition to the long-established heparins, hirudins, coumarins and antiplatelet drugs such as acetyl salicylic acid, nu-merous novel and predominantly synthetic pharma cologic agents have come onto the market in recent years.  ese new agents act at various sites in coagu-lation and have signicantly broadened treatment op-tions. Whilst immunological hypersensitivity reac-tions are on the whole rare, they have a considerable impact on patient management when they do occur.
 e present overview discusses the currently known hypersensitivity reactions to anticoagulant and anti-platelet agents, with particular attention to the newer substance classes including P2Y 12 inhibitors, glyco-protein IIb/IIIb receptor antagonists, direct factor Xa inhibitors and direct thrombin inhibitors.